Idecabtagene Vicleucel
B-Cell Chronic Lymphocytic Leukemia
Explore 67 assets in B-Cell Chronic Lymphocytic Leukemia →Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Bristol-Myers Squibb
Modality
Cell therapy
Development Phase
Unknown
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06357754CT.gov Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Chronic Lymphocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Idecabtagene Vicleucel (this asset) | Bristol-Myers Squibb | Unk | D · 30 |
| Humax-Cd20 | Emory University | P4 | BBB |
| Acalabrutinib | Zulfa Omer | P4 | BBB |
| Fludarabine | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Rituximab | Zulfa Omer | P4 | BBB |
| Cyclophosphamide | Ohio State University Comprehensive Cancer Center | P4 | BBB |
| Obinutuzumab | Paolo Caimi, MD | P3 | BB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Bendamustine | Mayo Clinic | P3 | BB |
+42 more in the B-Cell Chronic Lymphocytic Leukemia cohort
Other indications for Idecabtagene Vicleucel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P3 | CCC · 50 |
| Non-Hodgkin Lymphoma | — | Unk | D · 30 |
| Plasma Cell Leukemia | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Idecabtagene Vicleucel in B-Cell Chronic Lymphocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/idecabtagene-vicleucel-b-cell-chronic-lymphocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →